Results 161 to 170 of about 3,302 (197)

Morbus Crohn: Filgotinib bleibt eine Option zum Off-Label-Einsatz

Kompass Autoimmun
Zusammenfassung Die vorliegende Studie untersuchte die Wirksamkeit und Sicherheit von Filgotinib, einem oralen Januskinase-1-Inhibitor, bei Patient:innen mit Morbus Crohn.
E. Schnoy
semanticscholar   +1 more source

P0710 Effectiveness and Safety of Filgotinib After One Year in Patients with Ulcerative Colitis: Preliminary Results from the Filguito Registry in Andalusia (Spain)

Journal of Crohn's & Colitis
Filgotinib represents a novel therapeutic option for the treatment of moderate-to-severe ulcerative colitis. This observational study aims to evaluate the efficacy and safety of Filgotinib in real-world clinical practice.
A. C. Caballero Mateos, Á. Suárez-Toribio, C. Trigo-Salado, F. J. Rodríguez-González, E. Silva-Albarellos, M. M. Martín-Rodríguez, R. Gijón-Villanova, E. Gómez-Delgado, J. Benítez, A. M. Trapero-Martínez, Á. Hernández-Martínez, R. Olmedo-martín   +11 more
semanticscholar   +1 more source

Filgotinib for the Treatment of Refractory Collagenous Colitis

Journal of Crohn's and Colitis, 2023
Tomoyoshi Shibuya, Akihito Nagahara
openaire   +2 more sources

P0953 Real world effectiveness and safety of filgotinib in Ulcerative Colitis: 1 year follow-up results of the ICC registry

Journal of Crohn's & Colitis
Filgotinib is a preferential JAK1-inhibitor approved for the treatment of ulcerative colitis (UC). The ICC registry was developed to evaluate the effectiveness and safety of advanced therapies in inflammatory bowel disease (IBD).
M. Naber, A. E. van der Meulen, P. Voorneveld, A. V. van Bodegraven, M. Duijvestein, M. Pierik, L. Verleye, A. Bodelier, D. Bouwknegt, M. Visschedijk, R. West, S. van der Marel, P. Mensink, A. D. de Vries, T. Römkens, B. Oldenburg, M. Löwenberg, F. van Schaik   +17 more
semanticscholar   +1 more source

Filgotinib for ulcerative colitis

Nature Reviews Gastroenterology & Hepatology, 2021
openaire   +2 more sources

P0800 Efficacy of filgotinib in patients with ulcerative colitis refractory to prior biologics

Journal of Crohn's & Colitis
Filgotinib has shown promise for patients with moderate-to-severe Ulcerative Colitis (UC) who are refractory to prior biologics. Given the need for effective alternatives in this challenging patients, this study examines the efficacy of filgotinib ...
A. Suarez, P. Ruz Zafra, E. Leo Carnerero, M. Rojas Feria, M. D. de la Cruz Ramírez, A. R. Rodríguez Pérez, Á. M. Villalba Moreno, C. Trigo Salado   +7 more
semanticscholar   +1 more source

Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis

International Journal of Rheumatic Diseases
ABSTRACTAimTo compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).MethodsThis retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan–Meier curves, with the log‐rank test
Hironobu Kosugiyama, Shuji Asai, Kenya Terabe, Tomonori Kobayakawa, Yutaka Yoshioka, Tatsuo Watanabe, Toshihisa Kojima, Yasumori Sobue, Takefumi Kato, Takayoshi Fujibayashi, Yuji Hirano, Tsuyoshi Nishiume, Mihoko Kato, Yasuhide Kanayama, Toki Takemoto, Masahiro Hanabayashi, Hiroyuki Matsubara, Mochihito Suzuki, Ryo Sato, Junya Hasegawa, Yusuke Ohno, Takaya Sugiura, Nobunori Takahashi, Shiro Imagama   +23 more
openaire   +2 more sources

Filgotinib/prednisolone

Reactions Weekly, 2023
openaire   +1 more source

Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)

Modern Rheumatology, 2022
Tatsuya Atsumi, Edward Keystone, Eiji Sugiyama   +2 more
exaly  

Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials

Modern Rheumatology, 2022
Arthur Kavanaugh, Yoshiya Tanaka, Iain B Mcinnes   +2 more
exaly